Benitec Biopharma Annual Update 2015; Lists on the NASDAQ

Benitec Biopharma (ASX:BLT; NASDAQ:BNTC) is a clinical-stage, biotechnology company developing therapeutics based on its patented gene-silencing technology called ddRNAi.

Its unique therapies target specific genes, genetic disorders and infectious diseases including hepatitis C and B, wet Age-related Macular Degeneration (AMD) and Oculopharyngeal Muscular Dystrophy (OPMD). Benitec’s strategy is to develop its technology in-house, through partnerships with other biotechnology and pharma companies, as well as through out-licensing collaborations.

This year, the company has successfully listed on the NASDAQ, released positive in vitro data for its hepatitis B program and announced encouraging preliminary data from its Phase I/IIa hepatitis C clinical trial, the company’s lead program.

Benitec has a cash position, at 30 September 2015, of approximately AU$33 million. We expect to have significant advances on all of our programs in the next 12 months.

ABOUT BENITEC BIOPHARMA LIMITED

Benitec Biopharma Limited is a publicly listed (ASX:BLT) biotechnology company whose key assets are exclusive irrevocable worldwide rights to a platform technology which has the potential to permanently silence any gene associated with human diseases or conditions. Benitec Biopharma is demonstrating the efficacy and safety of this technology through collaboration with leading organisations globally.